Sort
23,748 grants matching “melanoma”
Bifunctional Antibodies for Melanoma Therapy
$442,736Peter M Glazer · Yale University · R01 · FY2015 · CA
Bifunctional Antibodies for Melanoma Therapy
$442,736Peter M Glazer · Yale University · R01 · FY2016 · CA
Liquid biopsy-based toolkits for neoantigen and cognate TCR discovery for cancer immunotherapy
$442,712Wei Wei · Institute For Systems Biology · R33 · FY2023 · CA
Penn Small Animal Imaging Resource (Penn-SAIR)
$442,700Jerry D Glickson · University Of Pennsylvania · U24 · FY2010 · CA
Developmental Funds
$442,591Henry Shelton Earp · Univ Of North Carolina Chapel Hill · P30 · FY2013 · CA
IMMUNOTHERAPEUTIC TARGETING OF SLC39A9 IN CDKN2A-LOW MELANOMA
$442,557The Wistar Institute Of Anatomy And Biology · · FY2025 · Defense Health Agency
Clonal analysis of the cranial neural crest
$442,533Marianne Bronner-Fraser · California Institute Of Technology · R01 · FY2021 · DE
Project III: Engineering immunogenic cell death in melanoma and renal cell carcinoma.
$442,500Emily H Cheng · Sloan-Kettering Inst Can Research · U54 · FY2025 · CA
Selective inhibition of nitric oxide synthase for multiple indications
$442,429Richard B Silverman · Northwestern University · R35 · FY2020 · GM
Clinical Trail of Vaccine in Combination with Toll-Like Receptor (TLR)
$442,258Patrick Hwu · University Of Tx Md Anderson Can Ctr · P01 · FY2010 · CA
TCR-like antibodies for HPV-induced cancer basic research and theranostics
$442,253Roland K Strong · Fred Hutchinson Cancer Research Center · R01 · FY2016 · AI
Targeting melanoma promoting RNA modification pathway for melanoma therapy.
$442,236Narendra Wajapeyee · University Of Alabama At Birmingham · R01 · FY2025 · CA
Platelet Serine/Threonine Phosphatases in Cancer Pathophysiology
$442,222K. Vinod Vijayan · Baylor College Of Medicine · R01 · FY2021 · CA
(PQ10) The impact of the gut microbiome on the anti-tumor effects of radiotherapy
$442,221Andrea Facciabene · University Of Pennsylvania · R01 · FY2021 · CA
The identification of genetic determinants of melanoma recurrence
$442,152Tomas Kirchhoff · New York University School Of Medicine · R01 · FY2019 · CA
Strategies to improve the adoptive transfer of T cells
$442,047Stanley R Riddell · Fred Hutchinson Cancer Research Center · R01 · FY2012 · CA
Humanized mouse models to dissect in vivo the interplay between melanoma and the immune system
$442,010Anna Karolina Palucka · Jackson Laboratory · R01 · FY2016 · CA
Palliative Care: Maximizing Patient Preference
$441,993Donald H Taylor · Duke University · R01 · FY2012 · HS
Allosteric inhibitors targeting oncogenic BRAF V600E dimers
$441,985Evripidis Gavathiotis · Albert Einstein College Of Medicine · R01 · FY2022 · CA
Allosteric inhibitors targeting oncogenic BRAF V600E dimers
$441,985Evripidis Gavathiotis · Albert Einstein College Of Medicine · R01 · FY2023 · CA
Developmental Funds
$441,875Henry Shelton Earp · Univ Of North Carolina Chapel Hill · P30 · FY2014 · CA
Phase I/II study of topical agents for chemoprevention
$441,844University Of Arizona · P01 · FY2005 · CA
Enhancing Tumor Antigen Presentation with Complement Targeted Nanoparticles
$441,796Max Peter Kullberg · University Of Alaska Anchorage · R15 · FY2022 · CA
Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs
$441,751Walter J Storkus · Roswell Park Cancer Institute Corp · P01 · FY2021 · CA
Overcoming primary and secondary resistance in wild-type BRAF melanoma
$441,736Andrew E Aplin · Wistar Institute · P01 · FY2023 · CA